Assessing activation states in microglia.
Since the original identification of microglia as a principal player in the brain's innate immune response, microglial activation has been widely studied. Recent studies suggest that microglial responses are heterogeneous, requiring a more precise definition of the functional outcomes of their participation in disease. Similarly to other tissue macrophages, microglia respond to inflammatory or injurious stimuli in the CNS in a pre-programmed manner that is designed to both kill and to set the stage for repair and resolution of the disease. In vitro studies on acute immune responses have provided key information on the initiation, signaling pathways and products of activated macrophages. However, in chronic neurodegenerative diseases such as Alzheimer's disease where in vivo analyses are critical to understanding the long-term disease processes, our knowledge of the integrated tissue immune response and the outcome of this immune activity to neurons and other glia over the extended course of disease is more limited. This is due in part to the complexity of microglial activation states and to the location of microglia in a dense neuronal network. Classical activation, alternative activation and acquired deactivation are each found in the brain during chronic neuroinflammatory diseases and may demonstrate regional differences in expression levels. This review will identify "markers" that can be used to explore inflammatory states in the brain and will discuss the likely functional outcomes when these cytoactive factors are expressed. A broad-based functional view is provided that is designed to more fully explore the balance between inflammo-toxic and inflammo-resolution factors that govern chronic disease progression.
Colton
Carol  A
C
Duke University Medical Center, Durham, NC 27710, USA. Carol.Colton@duke.edu
Wilcock
Donna M
DM
D000544:Alzheimer Disease / Q000276:immunology* / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D002465:Cell Movement / Q000276:immunology; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004660:Encephalitis / Q000276:immunology* / Q000503:physiopathology; D005911:Gliosis / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D007113:Immunity, Innate / Q000502:physiology; D017628:Microglia / Q000276:immunology*; D000074624:NADPH Oxidase 1; D019255:NADPH Oxidases / Q000378:metabolism
D018925:Chemokines; D016207:Cytokines; D000074624:NADPH Oxidase 1; D019255:NADPH Oxidases; C402799:NOX1 protein, human